Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | The promise of SEMA4D as a target in neurodegenerative diseases

Terrence Fisher, PhD, Vaccinex Inc., Rochester, NY, discusses the potential applications of the novel drug pepinemab in various neurodegenerative diseases. Pepinemab is a monoclonal antibody that inhibits the activity of SEMA4D, a protein that triggers glial cell activation and therefore may contribute to the pathophysiology of numerous neurodegenerative diseases. With demonstrated efficacy in Huntington’s disease trials, pepinemab holds promise for conditions like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, where the dysregulation of glial cells also occurs. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.